Trifluoroacetic acid → HCID 59437449, compound
Reaction equation
[CH3:1][O:2][C:3]1[CH:4]=[C:5]([C:17]2[CH:18]=[CH:19][C:20]3[N:21]([N:23]=[C:24]([NH:26][C:27](=[O:41])[C:28]4[CH:33]=[CH:32][C:31]([CH2:34][N:35]5[CH2:40][CH2:39][CH2:38][CH2:37][CH2:36]5)=[CH:30][CH:29]=4)[N:25]=3)[CH:22]=2)[CH:6]=[CH:7][C:8]=1[O:9]CC1C=CC=CC=1.FC(F)(F)C(O)=O>>[OH:9][C:8]1[CH:7]=[CH:6][C:5]([C:17]2[CH:18]=[CH:19][C:20]3[N:21]([N:23]=[C:24]([NH:26][C:27](=[O:41])[C:28]4[CH:29]=[CH:30][C:31]([CH2:34][N:35]5[CH2:40][CH2:39][CH2:38][CH2:37][CH2:36]5)=[CH:32][CH:33]=4)[N:25]=3)[CH:22]=2)=[CH:4][C:3]=1[O:2][CH3:1]Participants
3
Conditions
- Temperature
- 75 °C
Procedure
N-(6-{3-(methyloxy)-4-[(phenylmethyl)oxy]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)-4-(piperidin-1-ylmethyl)benzamide (14.9 mg, 0.027 mmol) was treated with trifluoroacetic acid (2 mL) and the reaction mixture was stirred for 1 hour at 75° C. The reaction mixture was cooled and the solvent removed in vacuo. The residue dissolved in DMSO (1.5 mL) and purified by reverse phase preparatory HPLC to give the title compound as a white solid (1.4 mg, 11%). HPLC, Rt: 2.23 min (purity: 99%). LC/MS M+(ESI): 458.2, M−(ESI) 456.2.
Workup
- temperatureThe reaction mixture was cooled
- customthe solvent removed in vacuo
- dissolutionThe residue dissolved in DMSO (1.5 mL)
- custompurified by reverse phase preparatory HPLC
Sources & evidence
- ORD record
- ord-a92790893bb246d1ba4893cecaaa3c48
- Source dataset
- uspto-grants-2012_09
- Patent number
- US08263595B2
Reaction notes
Loading…